PharVision Advisers’s Dillards DDS Stock Holding History

PharVision Advisers’s Portfolio DDS Stock Details DDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-661	Closed	-$401K	–	249
2025 Q4	$401K	Buy	+661	New	+$416K	0.2%	125

Other funds holding DDS

Newport Trust Company Washington, District of Columbia $40.7B AUM 24.62% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PharVision Advisers's DDS Position: Q1 2026 in Review

PharVision Advisers sold out of Dillards (DDS) in Q1 2026, closing a stake of 661 shares — an estimated $401K sold.

PharVision Advisers first reported a position in DDS in Q4 2025 and held it in 1 quarter. The position peaked at $401K in Q4 2025. 316 funds tracked by Wall St. Rank hold DDS as of Q1 2026.

PharVision Advisers reported no remaining Dillards position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 661 Dillards shares in Q1 2026, an estimated $401K.
PharVision Advisers first reported a position in Dillards in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Dillards position peaked at $401K in Q4 2025.
316 funds tracked by Wall St. Rank held Dillards as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.